S
Santhera Pharmaceuticals Holding AG (SPHDF)
PNK – Real Time Price. Currency in USD
23.25
0.00 (0.00%)
At close: Sep 4, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
PNK – Real Time Price. Currency in USD
23.25
0.00 (0.00%)
At close: Sep 4, 2026, 4:00 PM EDT
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
| Name | Position |
|---|---|
| Dr. Oliver P. Kronenberg Ph.D. | Chief Legal Officer & Corporate Secretary |
| Dr. Shabir Hasham M.D. | Chief Medical Officer |
| Dr. Thomas Meier Ph.D. | Founder & Chairman |
| Mr. Andreas Missy | Executive Vice President of Corporate Planning & Business Development |
| Mr. Marc Schrader | Chief Technology Officer |
| Mr. Neville Kodkani M.D. | Head of Global Marketing & Partner Management |
| Mr. Oliver Strub | Head of Compliance |
| Mr. Orlando Oliveira | Chief Executive Officer |
| Ms. Catherine Ann Isted A.C.M.A. | Chief Financial Officer |
| Ms. Sarah Holmes-Klotz | Global Head of People & Culture |
There is no data to display